Member Info for stu485

Wow !

You know when the Clown crew here doesn’t like the direction of travel in narrative and posts opposing their scripted nonsense when they Swarm and distract with multiple posts. Classic tactic!

Well I’m looking forward to making my apologies to Mr I & Haywire when the company is “ snapped up” in July .

…OR , maybe there’ll be no need?

As the clowns here like to say…tick tock!

AIMO

Glass,

Try this from Boom7, must be in your bin !!??

There are many more who’ve now got the measure of the man !

“Haywain….and his merry band of men25 Jun 2025 17:34

anyone seen haywain ?!!

not been brought out of mr india puppet box ….yet . mr india too busy holiding up the ****** card for the moment . i think you need to swap r that for a ramper card .

i seem to recall tuan receiving a lot of horrible abuse continually for stating out just how immorally and dishonest your ramping gang are …mr india don’t suppose you had any part of that name calling to tuan ..it’s different when it’s direct to someone not you isn’t it .

haywain bound to wheeled out from his superior soap box with more facts and figures to disguise the mess that this share actually really is . wasn’t it in fact haywain that said

“ the share price is irrelevant “ ….as it falls and falls

….why would it be irrelevant haywain , enlighten me

as most people have lost a lot of money . relevant .”

Haywire,

There’s no irony , you are so predictable !

I’m very encouraged others here have also ( somewhat belatedly) realized the twisting of facts and science within your posts to promote your bias.

So yes, let’s not consider the known difficulties in Car-t treatments of AML because they’re historical and couldn’t possibly apply to Hemogenyx trial…yeah right, hysterical!

Just to play along with Mr I & yourself, i’ll be the first to apologize when Hemogenyx are “snapped up” in July.

I don’t suppose the both of you would reciprocate if they’re not !!!?

Have a good day .

AIMO

Mr I,

Why are you now trying to back pedal on your post 08:39 today?

Let me help others understand.

You thought your baseless Ramp would go unchallenged .

When it was challenged and obvious that your future pump angle of a probable early efficacy RNS is being rightly unpicked, you’d rather not engage with any serious debate preferring to waffle on because you know it’s a inherently flawed argument for the reasons I’ve outlined.

Ramp on as I’m satisfied the facts will out.

Have a good day.

AIMO

Mr I,

Would you care to expand on why Hemogenyx could be “snapped up”in July ?

It is relatively common for Car-t trial treatments to initially promote a complete response in AML trials.

Very sadly and specifically in AML, it is also relatively common for that early CR to relapse with return of disease.

So can you please explain why bigpharma would choose to ignore these well known facts and “snap up” Hemogenyx without a reasonable clinically significant proof of durability and a statistically reasonable cohort treated ?

You might need Haywire’s help and many words to try and deflect from the fact;

Early efficacy signal(s) over a minimal cohort within r/r AML trials is unlikely to excite bigpharma.

Feel free to ramp away though, as is your job.

AIMO & DYOR

Pingu,

You’re now in the bin along with JHFH .

If by “on the cusp” you mean 2-3years as JRDC recently predicted, you might just possibly be correct.

Goodbye.

AIMO

A number of posters here have recently raised serious questions regarding the recent SP change and possible cause.

Q, Did those selling have prior knowledge of the senior scientist intention at Hemogenyx PRIOR to it becoming public knowledge?

Q, Should the company issue a RNS to announce the probable change of their top senior scientific team ?

I’m not going to comment on the first question.

The second question;

Yes i think there should be a RNS…Why?

One of the criteria requiring issuance is , “the news having a likely impact on SP if made public.”

Well i believe the news now public, has indeed impacted the SP.

Maybe one of the major LTH should seek clarification(s).

AIMO

JRDC,

I think the clown crew here will want you to wash your mouth out with soap after uttering 2-3years to wait!

I don’t disagree that big pharma generally want to see a greater cohort treated and particularly with r/r AML strong signs of a durable response, prior to investing the hundreds of millions some here have long since wrongly and repeatedly predicted.

The problem is, the Clown crew have been very actively misleading with their constant promise of a massive rerate at one point or another, which to date has proven to be complete fantasy.

Many here feel deceived and justifiably angry.

It’s well overdue the Clown crew shut up, retire, and let the company’s actions and progress determine investment opportunity or otherwise.

AIMO

mr i,

i agree , no place for ****** comments despite the extreme mitigating circumstances!

what ?

the fact you’ve been constantly encouraging pi’s to make investments with posts mostly of inappropriate financial advice .

no wonder there’s a great deal of resentment and anger aimed at you.

regarding reporting , unless you’re a professional financial advisor( i doubt very much), i’d carefully consider your own position and posting history as you’ll find there’s strict rules regards financial advice.

aimo

Haywire,

So a poster asks a genuine question regarding the high cost of autologous Car-T treatments possibly limiting demand, as a factor to consider as a potential investor,and your response “it’s irrelevant“… classic Haywire!

You are fully aware of many lower cost treatments & potential treatments, some highlighted here recently and by MD Anderson.

I know you would argue and it be true that Car-T has the potential for one off curatives whereas many other treatments types are only suitable bridging therapies and hence the potential for acceptable higher cost differential. All very true BUT, where does that argument lead to !?

Let me help, it leads to the need to demonstrate a deeper longer term response “Durability” which leads to a very significant time frame to prove, which in turn leads to what?

Still irrelevant to a potential investor ?

So the full and honest answer to the posters question is;

Cost is most definitely relevant. Dependent on the ability for a Car-T treatment to demonstrate far superior durability than other lower cost treatments , cost may or may not limit demand, regardless of geographic markets.

You again indirectly verify my argument that Efficacy is of little value without durability and when considering AML and the very sad propensity for post treatment relapse, durability is only proven over a very protracted timeframe.

Give the full answer next time …please.

AIMO

Haywire,

Already today you’ve;

Accepted i was correct and Kingpin was incorrect.

Realized i’d already answered and posted on the Paediatric expansion.My post also being accurate and proven correct.

Should you decide to answer my last question honestly , you’ve been a very good verifier of the accuracy in my postings , thanks.

I believe ,and think you may too, at the juncture the company now finds itself, there’s no need for the Clown Crew nonsense pumping statements here and it’s time for the science to do the talking . The crew here only tarnishing the company’s reputation with their ignorance and misleading and false statements .

Time for change.

AIMO

Haywire,

It would have been much clearer to all were you to have been less verbose and simply answered the question.

So yes despite all the clowns here trying to deflect, you concur, …i was correct and the Kingpin statement was BS.

Thank you.

To your question;

Why ? Because the company applied earlier than others and to date there’s no safety signals that would cause objection.

I think you’ll find , I’ve already posted this was my expectation . Have another coffee and check it out.

Now “ Efficacy without clinically significant durability”

I have posted on this subject because the crew here are already stating Hemo’ would have a “wonder drug” in a timeline where clinically significant durability could not have been proven and only early efficacy signal(s)

Would you like to state they’re correct or would you like to join the scientific side of the debate and agree, such a statement is very misleading particularly given the known issues with potential Car-T treatments of r/r AML.

Please take the red nose and big shoes off and be honest.

AIMO

Haywire,

Good morning to you.

Not sure if you’ve had a coffee yet but it seems you’ve completely overlooked the initial cause of debate and your requested comment on who was correct me or Kingpin?

Have a sip or two and then you can answer my first question after which i’ll then answer yours.

Thanks

AIMO

… if it’s ok with the Clown Crew here, I’ll wait for Haywire to respond with confirmation of the accuracy in my statement and Kingpins error.

Although he might be a little shy in coming forwards tail between his legs and most definitely will not want a grown up conversation on;

The previous response rates within similar Car-t AMl trials and the value of efficacy without clinically significant durability.

All scientifically speaking.

AIMO

Haywire,

My initial post was to call out the Kingpin false statement of “Hemo’ are the only organization with a potential Car-t treatment in trial for r/r AML” . Paraphrased.

They are not! There are many more.

Would you like to dispute my statement… Y/N?

Once you’ve accepted i was correct and that Kingpin was uttering pure BS, we can move onto “Efficacy” if you like where you can make another public admission confirming the accuracy of my further statements.

I will continue to call out BS here as and when i see it .

Have a nice day.

AIMO

Micky,

The crew who operate here on LSE don’t want you to know about the many other potential treatments for r/r AML , including many other Car-T trials.

What they REALLY don’t want you and others to know and understand is , just how common a complete response CR’s to Car-T treatments within R/R AML trials can be.

Why’s that ?

They’re looking forwards to an unchallenged mega pump with headlines such as “wonder drug” & “cure” should similar early efficacy and response levels be announced by the company to the examples i posted earlier.

The very sad reality is , it is also common for the initial response to diminish and patience relapse.

The crew’s mega pump likely being a false dawn.

They know it but they’d much rather… you didn’t, for the obvious reason.

Putting the crew here to one side.

Hopefully in time (6months - 1year) and with a sufficient cohort, 18 stated for phase1,Durability in response is proven and the trial progress to P2&3.

AIMO

DYOR

HT,

I think you’re correct in that many Car-t trials do not proceed through to successful treatments due to various issues, Durability of response being a main one.

Also yes maybe one of the trials referenced may have been 4 years ago and if yes just imagine how much better efficacy results could be in the present day with potentially better targets !

However, if you’re suggesting that there are no other Car-t trials in progress for R/R AML , then i think you need another chat with Mr Google and a closer look at Penn Uni !

AIMO

Kingpin,

I’m afraid you’ve triggered the BS meter !

Just to correct your false statement that Hemo’ are the only player with a potential Car-T treatment for r/r AML.

A very simple search (below) proves you wrong and will give links to the competitors trial details should you wish to properly research, …i suspect you’d rather not !

“Key aspects of CAR-T cell therapy in R/R AML:

Promising results in some trials:

Some clinical trials have reported encouraging outcomes, including complete remission rates and molecular remissions in patients with R/R AML. For example, one trial reported a 72% complete remission rate at 14 days post-CAR therapy in a cohort of 32 patients with AML, according to research from blood journal. Another trial showed that 10 out of 11 pediatric patients with R/R AML achieved a response (including complete remission or partial remission with undetectable minimal residual disease) after being infused with CLL-1 or CLL-1-CD33 dual CAR T-cells, according to a report from PMC.”

AIMO

DYOR

Micky,

Yes.

Considering the RNS communicating the FDA application for expansion to paediatric patients , it would seem appropriate to communicate FDA acceptance upon receipt.

AIMO

Hik,

Knowing the company have been through a lengthy learning experience with FDA submissions, combined with

the Adult initial safety criteria being satisfied for P1&2. Unless there’s a change to the safety indicators within the interim, I wouldn’t envisage an FDA objection.

AIMO